A clear look at what laboratory studies suggest, what human research actually shows, and where important questions remain.
AOD-9604 molecular structure · Image supplied for this profile
Chemical structure & identity
AOD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone. It contains 16 amino acids, including two cysteine residues joined by a disulfide bond. Its molecular structure is distinct from full-length growth hormone.
The chemical drawing identifies the molecule; it does not establish clinical effectiveness or safety.
Research at a Glance
InvestigationalWhat is AOD-9604?
AOD-9604 is a laboratory-developed peptide originally investigated for its potential effects on fat metabolism and weight management.
It was designed from a small section of human growth hormone (hGH), a naturally occurring protein involved in growth, metabolism, and body composition. Researchers wanted to find out whether they could isolate some of the hormone’s fat-related activity without reproducing its broader hormonal effects.
That question led to the development of AOD-9604. A peptide is simply a short chain of amino acids—the building blocks of proteins.
How is it thought to work?
Early research focused on two processes:
- Fat breakdown (lipolysis): Breaking down stored fat into components that can be released and used for energy.
- Fat formation (lipogenesis): The process of creating new fat that may be stored in the body.
Animal and laboratory findings suggested that AOD-9604 could encourage fat breakdown and influence fat formation. Unlike full growth hormone, it does not appear to act through the traditional growth hormone receptor or meaningfully raise IGF-1 levels in the human studies conducted.
The precise molecular pathway responsible for its reported effects remains incompletely established. Proposed effects on lipolysis and lipogenesis arose largely from laboratory and animal work; they have not translated into demonstrated clinically meaningful weight loss in the largest human trial.
What has research found?
Animal research: Early promise
In some animal models, AOD-9604 influenced fat metabolism and reduced weight gain. These results gave researchers a reason to investigate the compound in humans, but animal findings alone cannot establish human effectiveness.
Human research: The larger trial did not confirm the promise
AOD-9604 was evaluated in several clinical trials involving approximately 900 people, primarily adults with obesity. An earlier 12-week trial suggested greater average weight loss with one oral dose than with placebo, but the response was not consistent across doses.
In a larger 24-week trial enrolling 536 participants, AOD-9604 did not produce a statistically significant weight-loss advantage over placebo when participants followed a diet and exercise program. The study failed to meet its primary efficacy objective, and the company subsequently ended its obesity drug development program. This negative result carries substantial weight when evaluating the earlier, smaller trial.
What do we know about safety?
Published pooled safety findings from the human clinical program generally reported that AOD-9604 was well tolerated over the study periods. Researchers did not identify a consistent rise in IGF-1, deterioration in glucose regulation, or a clear excess of common adverse events compared with placebo.
Those findings have important boundaries. Most participants received oral AOD-9604, and some early work used intravenous administration. They do not establish the safety of repeatedly injected formulations or long-term use. Manufacturing quality, impurities, and potential immune responses are additional concerns for peptide products.
Is AOD-9604 FDA-approved?
No. AOD-9604 is not FDA-approved for weight loss or any other medical condition. FDA advisory committee materials have examined its proposed use in compounding and discussed limitations in available evidence and safety information.
AOD-9604 is also prohibited in sport under anti-doping rules applicable to growth hormone fragments.
Understanding the research limitations
- Animal results are not human proof. Metabolic effects in rodents may not translate into meaningful outcomes in people.
- Early signals require confirmation. The larger human trial failed to confirm clinically meaningful weight-loss benefits.
- How a compound is administered matters. Oral and intravenous study results cannot be assumed to apply to subcutaneous injections.
- Biological activity is not clinical benefit. Changing a laboratory marker or pathway is different from improving a health outcome.
- Not all findings are equally documented. Some historical efficacy results are described in regulatory materials and company reports rather than full peer-reviewed trial publications.
The bottom line
AOD-9604 illustrates an intriguing research strategy: isolating a small part of a larger hormone to study a narrower biological effect. Early laboratory and animal studies suggested activity related to fat metabolism, but the largest human obesity trial did not demonstrate meaningful weight-loss benefits.
Further well-designed research would be needed to establish any useful clinical application, particularly for injectable formulations.
Beyond the Research: What People Are Reporting
AOD-9604 has attracted interest among people discussing weight management, body composition, and stubborn body fat. Personal accounts vary widely, and the following are themes described in informal discussions—not verified clinical outcomes.
- Stubborn body fat: Some people describe gradual changes around the abdomen or waist.
- Body composition: Some report looking leaner or noticing changes in clothing fit, even without much change on the scale.
- Subtle changes: Positive accounts often describe gradual rather than dramatic results.
- Diet and exercise: Many discussions involve simultaneous lifestyle changes, making it difficult to isolate any effect of the peptide.
- Mixed experiences: Others report little or no noticeable difference in weight or appearance.
Putting these experiences into perspective
Body weight, waist measurements, and appearance can change for many reasons, including food intake, activity, hydration, and ordinary fluctuations. Many personal accounts also concern injected products, whereas most controlled human trials studied oral AOD-9604. These accounts cannot establish the safety or effectiveness of injections.
The takeaway: Interest in AOD-9604 often centers on perceived changes in stubborn body fat and body composition. Individual reports are mixed, and the largest controlled human trial did not establish meaningful weight-loss benefit.
These anecdotal themes are descriptive summaries of informal public discussion, not systematically collected or independently verified reports. They should not be interpreted as evidence of safety or effectiveness.
Scientific references & source documents
Primary research and regulatory documents are prioritized. Links lead to external sources; publication and regulatory details should be rechecked periodically.
- Stier H, Vos E, Kenley D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 3(1–2):7–15. Read publication ↗Pooled human clinical safety analysis; interpret in light of author affiliations and studied routes.
- U.S. Food and Drug Administration. (2024). Pharmacy Compounding Advisory Committee meeting, December 4, 2024. FDA meeting and supporting materials ↗Regulatory discussion and evidence assessment.
- U.S. Food and Drug Administration. (2024). AOD-9604-related bulk drug substance review. FDA briefing document (PDF) ↗Historical clinical efficacy data, formulation questions, and safety considerations.
- PubChem, National Library of Medicine. AOD-9604 compound and structural information. Search PubChem ↗
How to interpret these references
Peer-reviewed publications, regulatory reviews, and historical company-reported results serve different purposes. A regulatory briefing can summarize unpublished data, but it does not turn those data into independently peer-reviewed findings. No single source establishes safety or effectiveness for all formulations.
Updated: October 2026 · PepNexus Research, a Link2 Nutrition Research Initiative.